Literature DB >> 14693558

In vitro activities of tigecycline against erythromycin-resistant Streptococcus pyogenes and Streptococcus agalactiae: mechanisms of macrolide and tetracycline resistance.

C Betriu1, E Culebras, I Rodríguez-Avial, M Gómez, B A Sánchez, J J Picazo.   

Abstract

The activity of tigecycline was tested against erythromycin-resistant streptococci (107 Streptococcus pyogenes and 98 Streptococcus agalactiae strains). The presence of erythromycin and tetracycline resistance genes was determined by PCR. Among S. pyogenes strains the most prevalent gene was mef(A) (91.6%). The erm(B) gene was the most prevalent (65.3%) among S. agalactiae strains. Tigecycline proved to be very active against all the isolates tested (MIC at which 90% of the isolates tested were inhibited, 0.06 micro g/ml), including those resistant to tetracycline.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14693558      PMCID: PMC310199          DOI: 10.1128/AAC.48.1.323-325.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

2.  Emerging erythromycin resistance among group B streptococci in Korea.

Authors:  Y Uh; I H Jang; G Y Hwang; K J Yoon; W Song
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-01       Impact factor: 3.267

3.  Expression of resistance to tetracyclines in strains of methicillin-resistant Staphylococcus aureus.

Authors:  K Trzcinski; B S Cooper; W Hryniewicz; C G Dowson
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

4.  Genetic basis of antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital.

Authors:  Claire Poyart; Laurence Jardy; Gilles Quesne; Patrick Berche; Patrick Trieu-Cuot
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

5.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

6.  Prevalence of macrolide and tetracycline resistance mechanisms in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin.

Authors:  Carmen Betriu; Esther Culebras; Montserrat Redondo; Iciar Rodríguez-Avial; María Gómez; Ana Boloix; Juan J Picazo
Journal:  J Antimicrob Chemother       Date:  2002-09       Impact factor: 5.790

7.  GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria.

Authors:  L M Deshpande; A C Gales; R N Jones
Journal:  Int J Antimicrob Agents       Date:  2001-07       Impact factor: 5.283

8.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.

Authors:  Carmen Betriu; Iciar Rodríguez-Avial; Blas Ali Sánchez; María Gómez; Juan Alvarez; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

10.  Erythromycin and clindamycin resistance and telithromycin susceptibility in Streptococcus agalactiae.

Authors:  C Betriu; E Culebras; M Gómez; I Rodríguez-Avial; B A Sánchez; M C Agreda; J J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

View more
  9 in total

1.  Distribution of antimicrobial resistance and virulence-related genes among Brazilian group B streptococci recovered from bovine and human sources.

Authors:  Rafael S Duarte; Bruna C Bellei; Otávio P Miranda; Maria A V P Brito; Lúcia M Teixeira
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Macrolide and tetracycline resistance and emm type distribution of Streptococcus pyogenes isolates recovered from Turkish patients.

Authors:  Devrim Dundar; Murat Sayan; Gulden Sonmez Tamer
Journal:  Microb Drug Resist       Date:  2010-07-12       Impact factor: 3.431

3.  Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.

Authors:  Johannes Breedt; Jüri Teras; Janis Gardovskis; Frans Jacobus Maritz; Tiit Vaasna; Douglas Patrick Ross; Martine Gioud-Paquet; Nathalie Dartois; Evelyn J Ellis-Grosse; Evan Loh
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.

Authors:  Gopal Muralidharan; Richard J Fruncillo; Marlynne Micalizzi; Donald G Raible; Steven M Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Comparative in vitro antimicrobial activity of tigecycline, a new glycylcycline compound, in freshly prepared medium and quality control.

Authors:  Steven D Brown; Maria M Traczewski
Journal:  J Clin Microbiol       Date:  2007-05-09       Impact factor: 5.948

6.  Streptococcus agalactiae from pregnant women: antibiotic and heavy-metal resistance mechanisms and molecular typing.

Authors:  B Rojo-Bezares; J M Azcona-Gutiérrez; C Martin; M S Jareño; C Torres; Y Sáenz
Journal:  Epidemiol Infect       Date:  2016-08-08       Impact factor: 4.434

Review 7.  Antibiotics for treatment of resistant gram-positive coccal infections.

Authors:  Hossam Al-Tatari; Nahed Abdel-Haq; Pimpanada Chearskul; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319

8.  Secondary Metabolites of Antarctic Fungi Antagonistic to Aquatic Pathogenic Bacteria.

Authors:  Huibin Zhao; Chuner Cai; Xiaoyu Liu; Binghua Jiao; Bo Chen; Menghao Cai; Peimin He
Journal:  Open Life Sci       Date:  2018-03-20       Impact factor: 0.938

9.  Genetic commonality of macrolide-resistant group A beta hemolytic streptococcus pharyngeal strains.

Authors:  Angela L Myers; Mary Anne Jackson; Rangaraj Selvarangan; Richard V Goering; Christopher Harrison
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-12-01       Impact factor: 3.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.